CRESCENT BIOPHARMA, INC. — Director's Dealing 2021

Nov 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-11-16

Reporting Person: Andrews Patricia S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-16	Common Stock	P	40000	$2.05	Acquired	45250	Direct

Footnotes

F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $2.03 to $2.07 per share, with a weighted average purchase price of $2.05 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.